NCT05281783

RFA for Treatment of Intermediate Stage HCC

Efficacy and Response Predictors of Percutaneous Radiofrequency Ablation for Treatment of Intermediate Stage Hepatocellular Carcinoma: A Controlled Clinical Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Benha University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

In Egypt, chronic hepatitis C virus (HCV) is the most prevalent cause of hepatoma. The study aims to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC). The present study was a single-center, prospective non-randomized, controlled clinical trial in the Interventional Ultrasonography Unit, Tropical Medicine Department, Beni-Suef University Hospitals, between October 2018 and August 2021. Abdominal ultrasonography and triphasic computerized tomography (CT) abdomen were used to diagnose HCC. The abdominal ultrasonography and a dynamic CT scan were performed six weeks following the ablation to assess treatment efficacy.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DEVICE	percutaneous radiofrequency ablation (RFA)	We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).

Timeline

• Start date: 2018-10-01
• Primary completion: 2021-06-01
• Completion: 2021-08-01
• First posted: 2022-03-16
• Last updated: 2022-03-16

Locations

1 site across 1 country: Egypt